Drug-Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer

Article Oncology

Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model

Jing Jing et al.

Summary: This study developed a fit-for-purpose PBPK model to assess the clinical DDIs for Ipatasertib and provide dosing strategies for the concurrent use of other CYP3A4 perpetrators or victims.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

Mitigating ipatasertib-induced glucose increase through dose and meal timing modifications

Dhruvitkumar S. Sutaria et al.

Summary: This study evaluated the glucose changes in mCRPC patients treated with a combination of Ipatasertib, prednisone, and abiraterone. The results showed that this combination increased blood glucose levels, but administering it in the evening reduced peak glucose levels and improved the percentage of time within a certain range.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)

Add to Collection

Article Oncology

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib

Vikram Malhi et al.

Summary: Ipatasertib demonstrated rapid absorption and dose-proportionality in patients with refractory solid tumors, as well as moderate inhibition of CYP3A substrate. In clinical studies, ipatasertib at 600 mg can be administered with or without food.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects

Rucha S. Sane et al.

Summary: The study demonstrated that CYP3A4 plays a significant role in the clearance of ipatasertib, and that ipatasertib is not an inhibitor of organic anion transporting polypeptide 1B1/1B3. Additionally, it was shown that itraconazole did not impact CPI/CPIII levels in vivo. This finding enhances the understanding and application of these endogenous substrates and itraconazole in complex drug interaction studies.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2021)

Add to Collection

Article Oncology